Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
19 Results for "
PR EOS
" in MedChemExpress (MCE) Product Catalog:
Products (19)
19 Results for "PR EOS" in MCE Product Catalog:
3
Research Areas:
PF-06840003 (EOS200271) is a highly selective, orally active and brain-penetrant IDO-1 inhibitor with IC50s of 0.41 μM, 0.59 μM, and 1.5 μM for hIDO-1, dIDO-1, and mIDO-1, respectively .
3
Target:
Research Areas:
1
Target:
Research Areas:
Inupadenant is an orally active, highly selective A2A receptor antagonist. Inupadenant can not cross BBB. Inupadenant can enhance the humoral immune response and has anti-tumor activity .
1
1 Cited Publications
Synonyms: TωMCA sodium
Target:
Research Areas:
Tauro-ω-muricholic acid sodium (TωMCA sodium) is a bile acid released by the liver and an analog of tauro-α-muricholic acid. Tauro-ω-muricholic acid sodium is investigated as a potential marker in plasma for early-onset neonatal sepsis (EOS) and cholestasis studies
1
1 Cited Publications
Synonyms: EOS-850 hydrochloride
Target:
Research Areas:
Inupadenant (EOS-850) hydrochloride is an orally active, highly selective A2A receptor antagonist. Inupadenant hydrochloride can not cross BBB. Inupadenant hydrochloride can enhance the humoral immune response and has anti-tumor activity .
Cat. No.: HY-P991621
Synonyms: EOS-215
Target:
Research Areas:
EOS006215 (EOS-215) is a humanized monoclonal antibody targeting TREM-2. EOS006215 competes with TREM2 ligands, prevents TREM2 multimerization, and blocks downstream signaling. EOS006215 inhibits efferocytosis, reprograms transcriptomic profiles of monocyte-derived macrophages, alters metabolism and immune response genes, and increases pro-inflammatory marker secretion. EOS006215 reduces metastasis burden, delays tumor growth, and reprograms the tumor microenvironment to overcome anti-PD-1 resistance. EOS006215 can be used for the research of triple negative breast cancer and colorectal cancer .
Cat. No.: HY-173630
Target:
Research Areas:
BMS-986449 is a potent and orally active CELMoD molecular glue and an IKZF2/IKZF4 degrader. BMS-986449 targets the degradation of transcription factors Helios (IKZF2) and Eos (IKZF4) in regulatory T (Treg) cells. BMS-986449 redirects the E3 ubiquitin ligase Cereblon to induce the degradation of Helios and Eos, reprogramming Treg cells and enhancing antitumor immunity. BMS-986449 is promising for research of advanced solid tumors .
Cat. No.: HY-159650
CAS No.: 2724937-55-5
Target:
Research Areas:
EOS-984 is a macrocyclic diamine equilibrative nucleoside transporter 1 (ENT1) inhibitor. EOS984 inhibits ENT1 and ENT1-mediated nucleoside transport, restricting adenosine entry into cells via ENT1, thereby attenuating ATP-derived adenosine-mediated T cell immunosuppression and restoring primary human T cell proliferation. EOS984 can be used in research related to ENT1-mediated nucleoside transport, adenosine-related immunosuppression, and tumor immunity .
Cat. No.: HY-P990032
CAS No.: 2574438-65-4
Synonyms: EOS-448; EOS884448; GSK4428859A
Target:
Research Areas:
Cat. No.: HY-173630A
Target:
Research Areas:
(R)-BMS-986449 is the racemic mixture of BMS-986449 (HY-173630). BMS-986449 is a CELMoD molecular glue and an IKZF2/IKZF4 degrader. BMS-986449 targets the degradation of transcription factors Helios (IKZF2) and Eos (IKZF4) in regulatory T (Treg) cells. BMS-986449 redirects the E3 ubiquitin ligase Cereblon to induce the degradation of Helios and Eos, reprogramming Treg cells and enhancing antitumor immunity. BMS-986449 is promising for research of advanced solid tumors .
Cat. No.: HY-165066
CAS No.: 97040-38-5
Synonyms: N-(30-Linoleoyloxy-triacontanoyl)-sphingosine
Target:
Research Areas:
EOS (d18:1/30:0/18:2) is a kind ceramide in the outer epidermis .
Cat. No.: HY-152022S
CAS No.: 2692624-26-1
Synonyms: N-(32-lioleoyloxy-dotiacotaoyl)-sphigosie-d9
Target:
Research Areas:
EOS (d18:1/32:0/18:2)-d9 is the deuterium labeled EOS (d18:1/32:1/18:2) (HY-139393). EOS (d18:1/32:1/18:2) is a kind ceramide in the outer epidermis .
Cat. No.: HY-139393
CAS No.: 1318771-31-1
Synonyms: C52:3 EOS (18:1/32:1(22 Z)w18:2(9Z,12Z); Esterified ω-hydroxyacyl sphingosine
Target:
Research Areas:
EOS (d18:1/32:1/18:2) is a biochemical reagent.
Cat. No.: HY-113635
CAS No.: 99659-62-8
Research Areas:
ONO-6240 is a platelet-activating factor antagonist. ONO-6240 prevents EOS infiltration into airway. ONO-6240 can be used in the study of asthmatic .
Cat. No.: HY-189613
Target:
Research Areas:
EOS34295 is a dipeptidyl peptidase-IV (DPP-IV) inhibitor predicted to have oral activity. EOS34295 competitively binds to key residues in the active site of DPP-IV, inhibiting its enzymatic activity and blocking the degradation of incretins such as GLP-1/GIP, ultimately promoting insulin release to improve glycemic control. EOS34295 can be used in the study of type 2 diabetes .
Cat. No.: HY-175088
Synonyms: C48:2 EOP (t18:0/30:0w18:2 (9Z,12Z)); N-(30-Linoleoyloxy-triacontanoyl)-phytosphingosine
Target:
Research Areas:
EOP (t18:0/30:0/18:2) (C48:2 EOP (t18:0/30:0w18:2 (9Z,12Z)); N-(30-Linoleoyloxy-triacontanoyl)-phytosphingosine) is a plant ceramide-based EOS analog. EOP (t18:0/30:0/18:2) is formed by esterifying an ω-hydroxy very long chain ceramide (C28-36) with the essential fatty acid linoleic acid. EOP (t18:0/30:0/18:2) has been used as a component of a model stratum corneum lipid mixture .
Cat. No.: HY-RS16338
Target:
Research Areas:
EOS Human Pre-designed siRNA Set A contains three designed siRNAs for EOS gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-101111R
CAS No.: 198474-05-4
Synonyms: EOS200271 (Standard)
Research Areas:
PF-06840003 (Standard) is the analytical standard of PF-06840003 (HY-101111). This product is intended for research and analytical applications. PF-06840003 (EOS200271) is a highly selective, orally active and brain-penetrant IDO-1 inhibitor with IC50s of 0.41 μM, 0.59 μM, and 1.5 μM for hIDO-1, dIDO-1, and mIDO-1, respectively .
Cat. No.: HY-159978
CAS No.: 1628848-73-6
Synonyms: EOS789
Target:
Research Areas:
Atidafonat is an orally active sodium-dependent phosphate transporter inhibitor, with IC50 values of 6.8, 1.5, and 1.7 μM against human NaPi-IIb, PiT-1, PiT-2, respectively; and IC50 values of 3.9, 1.9, and 1.7 μM against rat NaPi-IIb, PiT-1, PiT-2, respectively. Atidafonat inhibits intestinal phosphate absorption, increases fecal phosphate excretion, reduces urinary phosphate excretion, and decreases the levels of serum phosphate, FGF23, and adult parathyroid hormone. Atidafonat ameliorates ectopic thoracic aortic calcification, renal injury and hyperphosphatemia, and inhibits the expression of fibrosis markers. Atidafonat can be used for the research of hyperphosphatemia and chronic kidney disease-mineral and bone disorder (CKD-MBD) .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
